In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Bioplastic straws an unlikely savior for coral
In Florida, researchers have developed a novel solution to keeping young, vulnerable coral from being eaten by predatory fish: protective cages made from bioplastic...
Canadian rapper Drake photographed sporting biobased EVA slip ons from Kane
In Canada, “Hotline Bling” rapper Drake has been seen sporting pink biobased slip-on shoes designed by Kane.
Founded in 2020 by former Maverik Lacrosse CEO...
Sorry parents, fruit waste glitter is still a pain to clean up
In the United Kingdom, scientists at Cambridge University have developed biodegradable glitter made from nanocrystals of cellulose extracted from fruit waste.
The sustainable sparkle solution...